Ariad plans $224M stock offering; Dicerna earns $5M milestone from KHK; Salk team touts potential of new Alzheimer's drug;

@FierceBiotech: Interesting model: Spectrum Pharma spinning gold from other companies' failures. Story | Follow @FierceBiotech

@JohnCFierce: BioSante is getting blasted on the failed libido gel study. Blames the dread placebo effect. Article | Follow @JohnCFierce

> Ariad Pharmaceuticals ($ARIA) is planning to raise $224 million through a stock offering to fund its final development work on the closely watched ponatinib. Ariad is planning an NDA next year. Story

> Dicerna Pharmaceuticals is pocketing a $5 million milestone payment from Kyowa Hakko Kirin as the pharma company takes the first oncology therapy into formal development. Release

> Boston-based Enlight Biosciences says it has formed new partnerships with AstraZeneca ($AZN) and Novo Nordisk ($NVO). As partners in Enlight, AstraZeneca and Novo Nordisk "will have the opportunity to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs." Release

> Glenmark is seeking arbitration to settle a dispute over its collaboration with Napo Pharmaceuticals. News

> Lux Biosciences has raised $4 million to support its work in ophthalmology. Story

Pharma News

@FiercePharma: Covidien plans to spin off pharma division into a separate company to better compete in the pain-management area. News | Follow @FiercePharma

> GAO: FDA needs more power to address drug shortages. Report

> Gilenya study results reveal no new safety issues. Story

Vaccine News

> Preclinical vaccine shrinks tumors 80%. Story

> Novartis opens doors to $1B vaccine plant. Article

> GE jumps in to biologics, vaccine manufacturing game. More

> Antigen Express vaccine cuts breast cancer recurrence. News

Pharma Manufacturing News

> Watch for pharma/carmaker collaboration pitfalls. More

> J&J releases Doxil batch; Ben Venue troubles detailed in FDA report. Article

> Novartis, HHS unveil pandemic-ready vax plant. Item

> Study finds substandard drugs cheaper than fakes. News

> Forecast: Pharma wants CMO consulting, regulatory support. Report

And Finally... Scientists at the Salk Institute for Biological Studies say that a mouse study has highlighted the potential of a new treatment for Alzheimer's. "J147 enhances memory in both normal and Alzheimer's mice and also protects the brain from the loss of synaptic connections," says David Schubert, the head of Salk's Cellular Neurobiology Laboratory, whose team developed the new drug. "No drugs on the market for Alzheimer's have both of these properties." Release